<DOC>
	<DOCNO>NCT00814970</DOCNO>
	<brief_summary>To evaluate safety efficacy Complete SE SFA Stent System treatment de novo and/or restenotic lesion occlusion Superficial Femoral Artery ( SFA ) and/or Proximal Popliteal Artery ( PPA ) subject symptomatic Peripheral Artery Disease ( PAD ) .</brief_summary>
	<brief_title>The Complete® SE SFA Study Treatment SFA/PPA Lesions</brief_title>
	<detailed_description>The Complete Self-Expanding ( SE ) SFA Stent design permanent implant . It cut nickel titanium alloy ( Nitinol ) tube consist series segment connect next unique pattern allow flexibility vessel conformability . Each segment consist two strut crown ( Figure 1 ) . It design produce optimal luminal diameter increase scaffolding , maintain luminal patency .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>1 . Rutherford 24 , occlusion de novo and/or restenotic SFA/PPA lesion ≥50 % anklebrachial index/toebrachial index ( ABI/TBI ) &lt; 0.90/0.80 . 2 . Target lesion locate least 1 cm distal takeoff profunda femoris artery least 3 cm proximal high point cortical margin femur ; 3 . Target vessel reference diameter ≥4.0 mm ≤7.0 mm ( visual estimate ) ; 4 . Target lesion length ≥4.0 cm ≤14.0 cm ( visual estimate ) ; 5 . Adequate distal runoff ankle target limb ( define least one patent calf vessel &lt; 50 % stenosed ; 6 . Life expectancy &gt; 12 month . 7 . Women negative serum urine pregnancy test document within 7 day prior enrollment ; 8 . Any condition precludes safe access percutaneous transluminal angioplasty ( PTA ) device , : excessive peripheral artery disease , unresolved fresh thrombus target lesion/vessel , target lesion/vessel excessively tortuous calcify ; 9 . Lesions contralateral SFA/PPA require intervention index procedure , within 30 day index procedure ; 10 . Previous treatment target lesion within 3 month prior enrollment ; previous femoropopliteal bypass target vessel ; previous stenting target lesion ; 11 . Target lesion locate within aneurysm associate aneurysm vessel segment either proximal distal target lesion ; 12 . Target lesion require treatment standard PTA prior stent placement ( i.e. , device procedure cut balloon laser atherectomy permit used index procedure ) ; 13 . History bleed diatheses coagulopathy refuse blood transfusion ; 14 . Known impaired renal function , define creatinine &gt; 2.5 mg/dl ; 15 . Known platelet count &lt; 80,000 cells/mm3 &gt; 700,000 cells/mm3 ; 16 . Known white blood cell ( WBC ) &lt; 3,000 cells/mm3 ; 17 . Participation another investigational device drug study complete primary endpoint ( ) clinically interfere Complete SE SFA Study endpoint , previously enrol Complete SE SFA Study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>PAD</keyword>
	<keyword>peripheral arterial disease</keyword>
	<keyword>stent</keyword>
	<keyword>SFA</keyword>
	<keyword>PPA</keyword>
</DOC>